We are an innovative clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. We believe our approach has the potential to fundamentally transform the therapeutic modulation of the immune system. Compounds derived from our proprietary Agonist Redirected Checkpoint, or ARC®, platform simultaneously inhibit checkpoint molecules and […]

We are a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need. We are initially developing our wholly owned product candidate, tildacerfont, as the potential first non-steroidal therapy to offer markedly improved disease control and reduce steroid burden for patients suffering from classic congenital adrenal hyperplasia, or […]

We are a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to transform patient outcomes through a precision medicine strategy by targeting dysregulated transcription. Our proprietary product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks (TRNs) that drive their oncogenic activity. Our lead product candidate, entospletinib […]

  We intend to focus our search for a target business in the value-added distribution, industrial specialty services, and differentiated manufacturing sectors. (Note: This SPAC deal was increased in size to 11 million units, up from 10 million, at $10 each to trade on the NASDAQ, according to an SEC filing on Oct. 22, 2020.)

We intend to capitalize on the expertise of our management team in the sports (including sports franchises or assets related to sports franchises, and sports technology), entertainment and brands sectors. We intend to focus on leading sports, entertainment and brand companies that have potential for brand and commercial growth with enterprise values between $300 million […]

We intend to initially focus on companies in the travel, hospitality, leisure, financial technology (fintech), insurance technology and property technology (PropTech) sectors. We believe that the dislocation caused by the coronavirus (COVID-19) pandemic will create significant value opportunities in these sectors.

We intend to focus our efforts for an initial business combination within the broader food and consumer products value chain, where significant technology innovation is occurring from accelerating eCommerce demand trends and disruption in supply chain logistics. (The prospectus notes the impact of the COVID-19 pandemic on consumers’ buying habits and the resulting disruption of […]

We intend to focus our search for a target business in industries that may provide opportunities for attractive risk-adjusted returns in one of the multiple sectors that may advance the objectives of global decarbonization. This includes the energy and agriculture, industrials, transportation and commercial and residential sectors. (This blank check company was formerly known as Silver […]

This is a new blank check company founded by Sir Richard Branson, the founder of the Virgin Group. From the prospectus: “We are focused on effecting a business combination with a target that operates in one of the Virgin Group’s core sectors: travel & leisure, financial services, health & wellness, technology & internet-enabled, music & entertainment, […]

This is a new dining, hospitality, entertainment and gaming-focused blank check company led by Tilman Fertitta of “Billion Dollar Buyer” fame on CNBC. He is the co-chairman and CEO of Landcadia Holdings III. Mr. Fertitta is the sole shareholder, chairman and CEO of FEI, an international dining, hospitality, entertainment, sports and gaming company. FEI is […]